Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib (Continuous vs. Intermittent) in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This is a Phase II, randomized, multi-centre study aiming at comparing the efficacy of Olaparib and Cediranib vs. weekly Paclitaxel in terms of progression free survival (PFS) in platinum refractory or resistant recurrent ovarian cancer.

Patients will be randomised in a 1:1:1 ratio to three treatment arms:

* Arm A: Paclitaxel 80 mg/mq every week
* Arm B: Cediranib 20 mg/day + Olaparib 600 mg / day (i.e. 300 mg BD) given every day
* Arm C: Cediranib 20 mg/day given 5 days per weeks + Olaparib 600 mg / day (i.e. 300 mg BD) given 7 days per weeks


Options:
A: Arm Label: Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: Nintedanib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin (PLD), Drug: Topotecan, Drug: Carboplatin, Drug: Doxorubicin | Intervention Type: DRUG; Name: Nintedanib; Assigned to Arm(s): Nintedanib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin (PLD); Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Chemotherapy
B: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
C: Arm Label: non platinum based chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Arm Label: platinum based chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Intervention Type: DRUG; Name: stealth liposomal doxorubicin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C

Answer: D